Header Logo

Connection

VICENTE VALERO to Adult

Back to Details
This is a "connection" page, showing publications VICENTE VALERO has written about Adult.
VICENTE VALERO
Connection Strength
0.731
Adult
  1. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
    View in: PubMed
    Score: 0.027
  2. Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas. 2017 08; 46(7):943-947.
    View in: PubMed
    Score: 0.024
  3. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg. 2016 Dec; 264(6):1073-1081.
    View in: PubMed
    Score: 0.023
  4. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.022
  5. Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg. 2016 Feb; 137(2):385-393.
    View in: PubMed
    Score: 0.022
  6. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015 Feb; 19(2):272-81.
    View in: PubMed
    Score: 0.020
  7. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract. 2014 Apr; 20(2):120-9.
    View in: PubMed
    Score: 0.018
  8. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer. 2012 Aug; 12(4):240-6.
    View in: PubMed
    Score: 0.017
  9. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9.
    View in: PubMed
    Score: 0.012
  10. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006 Apr; 17(4):605-13.
    View in: PubMed
    Score: 0.011
  11. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol. 2005 Aug; 16(8):1289-96.
    View in: PubMed
    Score: 0.010
  12. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D. 2005; 6(5):299-305.
    View in: PubMed
    Score: 0.010
  13. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
    View in: PubMed
    Score: 0.008
  14. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
    View in: PubMed
    Score: 0.008
  15. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.007
  16. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
    View in: PubMed
    Score: 0.007
  17. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream? in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020; 15(3):e0229903.
    View in: PubMed
    Score: 0.007
  18. [Third revision of the National Consensus on Diagnosis and Treatment of Breast Cancer (third of three parts)]. Ginecol Obstet Mex. 2010 Mar; 78(3):199-212.
    View in: PubMed
    Score: 0.007
  19. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.007
  20. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.007
  21. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.007
  22. The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Ann Surg. 2019 07; 270(1):147-157.
    View in: PubMed
    Score: 0.007
  23. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
    View in: PubMed
    Score: 0.007
  24. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
    View in: PubMed
    Score: 0.007
  25. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
    View in: PubMed
    Score: 0.007
  26. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
    View in: PubMed
    Score: 0.007
  27. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct; 16(10):3362-8.
    View in: PubMed
    Score: 0.007
  28. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One. 2018; 13(9):e0204372.
    View in: PubMed
    Score: 0.007
  29. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.007
  30. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
    View in: PubMed
    Score: 0.006
  31. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.006
  32. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577.
    View in: PubMed
    Score: 0.006
  33. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.006
  34. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.006
  35. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306.
    View in: PubMed
    Score: 0.006
  36. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018 Jan 01; 124(1):36-45.
    View in: PubMed
    Score: 0.006
  37. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park). 1997 Aug; 11(8 Suppl 8):34-6.
    View in: PubMed
    Score: 0.006
  38. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.006
  39. Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? Am J Surg. 2018 Apr; 215(4):693-698.
    View in: PubMed
    Score: 0.006
  40. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30; 8(22):35656-35668.
    View in: PubMed
    Score: 0.006
  41. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783.
    View in: PubMed
    Score: 0.006
  42. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.006
  43. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272.
    View in: PubMed
    Score: 0.006
  44. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431.
    View in: PubMed
    Score: 0.006
  45. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. Reg Anesth Pain Med. 2016 Nov/Dec; 41(6):696-703.
    View in: PubMed
    Score: 0.006
  46. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. 2016 10 10; 34(29):3511-3517.
    View in: PubMed
    Score: 0.006
  47. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77.
    View in: PubMed
    Score: 0.006
  48. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25.
    View in: PubMed
    Score: 0.005
  49. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66.
    View in: PubMed
    Score: 0.005
  50. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7.
    View in: PubMed
    Score: 0.005
  51. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94.
    View in: PubMed
    Score: 0.005
  52. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.005
  53. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
    View in: PubMed
    Score: 0.005
  54. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7.
    View in: PubMed
    Score: 0.005
  55. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23.
    View in: PubMed
    Score: 0.005
  56. A novel risk score that incorporates recipient and donor variables to predict 1-year mortality in the current era of lung transplantation. J Heart Lung Transplant. 2015 Nov; 34(11):1449-54.
    View in: PubMed
    Score: 0.005
  57. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 1995 Jul 15; 55(14):3060-7.
    View in: PubMed
    Score: 0.005
  58. The influence of institutional volume on the incidence of complications and their effect on mortality after heart transplantation. J Heart Lung Transplant. 2015 Nov; 34(11):1390-7.
    View in: PubMed
    Score: 0.005
  59. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
    View in: PubMed
    Score: 0.005
  60. Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. JAMA Surg. 2015 Jun; 150(6):547-53.
    View in: PubMed
    Score: 0.005
  61. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
    View in: PubMed
    Score: 0.005
  62. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.005
  63. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31.
    View in: PubMed
    Score: 0.005
  64. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015 Jan 09; 17:2.
    View in: PubMed
    Score: 0.005
  65. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014 Dec 30; 16(6):500.
    View in: PubMed
    Score: 0.005
  66. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.005
  67. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. Clin Breast Cancer. 2015 Feb; 15(1):37-42.
    View in: PubMed
    Score: 0.005
  68. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014 Aug; 146(3):477-86.
    View in: PubMed
    Score: 0.005
  69. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.005
  70. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
    View in: PubMed
    Score: 0.005
  71. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.005
  72. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
    View in: PubMed
    Score: 0.005
  73. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
    View in: PubMed
    Score: 0.004
  74. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34.
    View in: PubMed
    Score: 0.004
  75. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9.
    View in: PubMed
    Score: 0.004
  76. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
    View in: PubMed
    Score: 0.004
  77. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
    View in: PubMed
    Score: 0.004
  78. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
    View in: PubMed
    Score: 0.004
  79. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
    View in: PubMed
    Score: 0.004
  80. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
    View in: PubMed
    Score: 0.004
  81. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
    View in: PubMed
    Score: 0.004
  82. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
    View in: PubMed
    Score: 0.004
  83. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84.
    View in: PubMed
    Score: 0.004
  84. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
    View in: PubMed
    Score: 0.004
  85. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
    View in: PubMed
    Score: 0.004
  86. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95.
    View in: PubMed
    Score: 0.004
  87. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011 Jul 15; 129(2):417-23.
    View in: PubMed
    Score: 0.004
  88. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. 2010 Oct 26; 103(9):1331-4.
    View in: PubMed
    Score: 0.004
  89. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 Dec; 21(12):2348-2355.
    View in: PubMed
    Score: 0.004
  90. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.004
  91. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
    View in: PubMed
    Score: 0.004
  92. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9.
    View in: PubMed
    Score: 0.003
  93. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
    View in: PubMed
    Score: 0.003
  94. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.
    View in: PubMed
    Score: 0.003
  95. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul; 19(7):1255-1260.
    View in: PubMed
    Score: 0.003
  96. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Ann Oncol. 2006 Nov; 17(11):1644-9.
    View in: PubMed
    Score: 0.003
  97. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 01; 23(31):7820-6.
    View in: PubMed
    Score: 0.003
  98. Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 01; 23(31):7827-35.
    View in: PubMed
    Score: 0.003
  99. Liver abscess complicating Crohn's disease presenting as thoracic empyema. Case report and review of the literature. Am J Med. 1985 Nov; 79(5):659-62.
    View in: PubMed
    Score: 0.003
  100. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.003
  101. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
    View in: PubMed
    Score: 0.002
  102. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102.
    View in: PubMed
    Score: 0.002
  103. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21.
    View in: PubMed
    Score: 0.002
  104. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8.
    View in: PubMed
    Score: 0.002
  105. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.002
  106. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
    View in: PubMed
    Score: 0.002
  107. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.002
  108. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15; 19(10):2587-95.
    View in: PubMed
    Score: 0.002
  109. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001 May; 108(5):994-5.
    View in: PubMed
    Score: 0.002
  110. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1716-22.
    View in: PubMed
    Score: 0.002
  111. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71.
    View in: PubMed
    Score: 0.002
  112. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33.
    View in: PubMed
    Score: 0.002
  113. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
    View in: PubMed
    Score: 0.002
  114. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
    View in: PubMed
    Score: 0.002
  115. Minority cancer patients and their providers: pain management attitudes and practice. Cancer. 2000 Apr 15; 88(8):1929-38.
    View in: PubMed
    Score: 0.002
  116. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
    View in: PubMed
    Score: 0.002
  117. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.
    View in: PubMed
    Score: 0.002
  118. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000 Feb; 82(3):529-34.
    View in: PubMed
    Score: 0.002
  119. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
    View in: PubMed
    Score: 0.002
  120. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7.
    View in: PubMed
    Score: 0.002
  121. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
    View in: PubMed
    Score: 0.002
  122. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33.
    View in: PubMed
    Score: 0.002
  123. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998 Oct; 21(5):442-6.
    View in: PubMed
    Score: 0.002
  124. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol. 1998 Aug; 21(4):413-5.
    View in: PubMed
    Score: 0.002
  125. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8.
    View in: PubMed
    Score: 0.002
  126. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Mar 01; 82(5):965-9.
    View in: PubMed
    Score: 0.002
  127. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan; 16(1):187-96.
    View in: PubMed
    Score: 0.002
  128. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-77-S17-80.
    View in: PubMed
    Score: 0.002
  129. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21.
    View in: PubMed
    Score: 0.001
  130. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996 Jul; 35(1):74-8.
    View in: PubMed
    Score: 0.001
  131. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41.
    View in: PubMed
    Score: 0.001
  132. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
    View in: PubMed
    Score: 0.001
  133. Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an unusual case. Rev Infect Dis. 1986 Jan-Feb; 8(1):31-41.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.